References
- Isaacson P G. Gastric MALT-lymphoma: from concept to cure. Ann Oncol 1999; 10: 637–645
- Wotherspoon A C, Doglioni C, Diss T C, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342: 575–577
- Raderer M, Isaacson P G. Extranodal lymphoma of MALT-type: perspective at the beginning of the 21st century. Expert Rev Anticancer Ther 2001; 1: 53–64
- Wundisch T, Thiede C, Morgner A, Dempfle A, Gunther A, Liu H, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005; 23: 8018–8024
- Sackmann M, Morgner A, Rudolph B, Neubauer A, Thiede C, Schulz H, et al. Regression of gastric MALT-lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. Gastroenterology 1997; 113: 1087–1090
- Raderer M, Österreicher C, Machold K, Formanek M, Fiebiger W, Penz M, et al. Impaired response of gastric MALT lymphoma to Helicobacter pylori eradication in patients with autoimmune disease. Ann Oncol 2001; 12: 937–939
- Wohrer S, Streubel B, Bartsch R, Chott A, Raderer M. Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphoma. Clin Cancer Res 2004; 10: 7179–7181
- Liu H, Ye H, Ruskone-Fourmestraux A, De Jong D, Pileri S, Thiede C, et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122: 1286–1294
- Liu H, Ye H, Ruskone Fourmestraux A, Lavergne-Slove A, Ye H, Molin T, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001; 357: 39–40
- Ye H, Liu H, Raderer M, Chott A, Ruskone-Fourmestraux A, Wotherspoon A, et al. High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT-lymphoma. Blood 2003; 101: 2547–2550
- Raderer M, Streubel B, Wohrer S, Hafner M, Chott A. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut 2006; 55: 616–618, Epub 18 Nov 2005
- Copie-Bergman C, Gaulard P, Lavergne-Slove A, Brousse N, Flejou J F, Dordonne K, et al. Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma. Gut 2003; 52: 1656
- Inagaki H, Nakamura T, Li C, Sugiyama T, Asaka M, Kodaira J, et al. Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter pylori eradication and detection of API2-MALT1 fusion. Am J Surg Pathol 2004; 28: 1560–1567
- Ruskone-Fourmestraux A, Lavergne A, Aegerter P H, Megraud F, Palazzo L, Mascarel A, et al. Predictive factors of regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut 2001; 48: 297–303
- Ferreri A J, Guidoboni M, Ponzoni M, De Conciliis C, Dell'Oro S, Fleischhauer K, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004; 96: 586–594
- Grunberger B, Hauff W, Lukas J, Wohrer S, Zielinski C C, Streubel B, et al. ‘Blind’ antibiotic treatment targeting Chlamydia is not effective in patients with MALT lymphoma of the ocular adnexa. Ann Oncol 2006; 17: 484–487
- Nakase H, Okazaki K, Ohana M, Ikeda K, Uchida K, Uose S, et al. The possible involvement of micro-organisms other than Helicobacter pylori in the development of rectal MALT lymphoma in H. pylori-negative patients. Endoscopy 2002; 34: 343–346
- Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 2004; 117(Suppl 9A)5S–11S, Review